Skip to main content
Atrás
SRPT logo

Sarepta Therapeutics, Inc.

Calidad de datos: 100%
Sobrecompra
SRPT
NASDAQ Healthcare Biotechnology
$23.77
▲ $6.16 (34.98%)
Cap. Mercado: 2.50B
Rango del Día
$19.67 $23.85
Rango de 52 Semanas
$10.42 $76.67
Volumen
16,921,167
Promedio 50D / 200D
$18.99 / $20.15
Cierre Anterior
$17.61

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E -3.5 0.2
P/B 2.2 3.0
ROE % -53.5 3.6
Net Margin % -32.5 3.8
Rev Growth 5Y % 33.0 9.9
D/E 0.9 0.2

Precio Objetivo de Analistas

Hold
$24.50 +3.1%
Low: $16.00 High: $32.00
P/E Futuro
7.64
EPS Futuro
$3.11
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
1.71B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $1.35
$0.95 – $1.63
 1.42B 5
FY2029 $1.26
$0.89 – $1.51
 1.44B 10
FY2028 $1.03
-$2.98 – $4.60
 1.41B 12

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 -$1.20 -$3.58 -199.0%
2025-11-03 $0.01 -$0.13 -1400.0%
2025-08-06 $1.11 $2.02 +82.0%
2025-05-06 $0.35 -$3.42 -1077.1%
2025-02-26 $1.38 $1.50 +8.7%
2024-11-06 -$0.06 $0.62 +1139.7%
2024-08-07 $0.01 $0.07 +1201.1%
2024-05-01 $0.10 $0.73 +625.6%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 33.03% annually over 5 years — strong growth
Earnings declined -403.27% over the past year
Negative free cash flow of -307.45M
PEG of 0.01 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 17.45%
Capital efficient — spends only 4.64% of revenue on capex

Crecimiento

Revenue Growth (5Y)
33.03%
Revenue (1Y)15.58%
Earnings (1Y)-403.27%
FCF Growth (3Y)N/A

Calidad

Return on Equity
-53.47%
ROIC-22.63%
Net Margin-32.45%
Op. Margin-29.92%

Seguridad

Debt / Equity
0.91
Current Ratio2.32
Interest Coverage-67.60

Valoración

P/E Ratio
-3.50
Forward P/E7.64
P/B Ratio2.19
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 15.58% Revenue Growth (3Y) 32.97%
Earnings Growth (1Y) -403.27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33.03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2.20B Net Income (TTM) -713.41M
ROE -53.47% ROA -21.30%
Gross Margin 59.90% Operating Margin -29.92%
Net Margin -32.45% Free Cash Flow (TTM) -307.45M
ROIC -22.63% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.91 Current Ratio 2.32
Interest Coverage -67.60
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.50 Forward P/E 7.64
P/B Ratio 2.19 P/S Ratio 1.14
PEG Ratio 0.01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1.46 Fwd Earnings Yield 13.09%
FCF Yield -12.32%
Market Cap 2.50B Enterprise Value 2.73B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.20B 1.90B 1.24B 933.01M 701.89M
Net Income -713.41M 235.24M -535.98M -703.49M -418.78M
EPS (Diluted) -7.13 2.34 -5.80 -8.03 -5.15
Gross Profit 1.32B 1.58B 1.09B 793.02M 604.84M
Operating Income -657.77M 218.08M -267.82M -536.20M -459.71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3.35B 3.96B 3.26B 3.13B 3.15B
Total Liabilities 2.21B 2.44B 2.41B 2.74B 2.22B
Shareholders' Equity 1.14B 1.53B 859.34M 384.95M 928.01M
Total Debt 1.04B 1.34B 1.40B 1.62B 1.15B
Cash & Equivalents 801.28M 1.10B 428.43M 966.78M 2.12B
Current Assets 2.54B 3.07B 2.58B 2.56B 2.60B
Current Liabilities 1.10B 731.68M 653.66M 619.60M 452.73M

Puntuaciones de Estrategias

This stock passed the criteria for 0 strategies

Score = fit strength (0–100)
Rank = position among all matches

Actividad Reciente

Salió Price/Sales Ratio Focus (Ken Fisher)
Mar 26, 2026
Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026